7th International Conference on Clinical & Experimental Ophthalmology 2016
Crowne Plaza Dubai *DUBAI, UAE Visit the Venue to read more
The 7th International Conference on Clinical & Experimental Ophthalmology which is going to be held during November 21-23, 2016 at Dubai, UAE which brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostic companies, leading universities and clinical research institutions making the conference a perfect platform to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe. Ophthalmology 2016 maximizes the opportunity to interact with and learn from your peers from across the country and across the globe it held with the discussions on Retina and Retinal Disorders, Cornea and External Eye Disease Neuro-Ophthalmology, Glaucoma: Visual Field Loss, Ocular Microbiology and Immunology, Novel Approaches to Ophthalmology Therapeutics and many more.
OMICS International Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Retinal disorders, optic atrophy, and lesions of the higher visual pathways are the main anatomical causes of visual loss in children. WHO reports that, 285 million people are estimated to be visually impaired worldwide: 39 million are blind and 246 have low vision. About 90% of the world’s visually impaired live in low-income settings 82% of people living with blindness are aged 50 and above. Globally, uncorrected refractive errors are the main cause of moderate and severe visual impairment; cataracts remain the leading cause of blindness in middle- and low-income countries. Many European associations are involved in Ophthalmology and many eye banks are actively promoting the donation of eyes in Europe, addressing a gap in the ophthalmic market, the global ophthalmic market was valued at $10.3 billion in 2010 and is estimated to reach $13.2 billion in 2017.
Retina and Retinal Disorders
The retina is a thin layer of tissue on the inside back wall of your eye. It contains millions of light-sensitive cells and other nerve cells that receive and organize visual information. Your retina sends this information to your brain through your optic nerve, enabling you to see. Retinal degenerative disorders such as Age-related macular degeneration and Myopic macular degeneration affecting young and old from many cultures, races and ethnicities. The central area of the retina contains a high density of color-sensitive photoreceptor cells called cones which are responsible for color vision and hence any defect and alteration in the central area of the retina will lead to Color vision defects. On the other hand diseases like Diabetic retinopathy and Retinal tumors can also be responsible for the permanent vision loss if it is not treated on time. Historically, retinal disease has had a low priority in prevention of blindness programs in developing countries. There are several reasons for this. Firstly, it was thought that retinal disease was an uncommon cause of blindness in the developing world; secondly, that the results of treating retinal disease did not justify the effort and expense involved; and, thirdly, that the equipment required was too costly and unreliable for use in a developing country environment. Finally, there is a lack of skilled personnel with sub-specialty training in retinal disease. John Hopkins School of Medicine, UCSF School of Medicine, David Geffen School of Medicine and Mayo Medical School are the leading institutes associates with ophthalmology.
Cornea and External Eye Disease
Eye is composed of very sensitive and fragile tissues and every part of an eye serves its own function to maintain its normal vision. The cornea is the transparent front part of the eye that covers the iris, pupil, and anterior chamber. The cornea, with the anterior chamber and lens, refracts light, with the cornea accounting for approximately two-thirds of the eye's total optical power. But factors such as corneal ulceration, Epithelial keratitis & drug-induced epithelial keratitis, corneal regeneration, recurrent corneal erosion and miscellaneous corneal disorders can affect the cornea and ultimately lead to the external eye disease that could end up with permanent blindness. Hence investigation of corneal disease is carry out to mitigate the disease and methods like Contact lenses & vision correction is also use to cure the vision related problems and surgical procedure like corneal transplantation is used to transplant the cornea. According to international council of ophthalmology 2012 report there were 206,812 practicing ophthalmologists around the world and there are approximately 23,861 ophthalmologists in the United States, as per the records of American Medical Association.
Glaucoma: Visual Field Loss
Glaucoma is a multifactorial optic neuropathy that affects more than 50 million people and is the second leading cause of blindness worldwide. The role of intra ocular pressure (IOP) has been well documented as a major modifiable risk factor for glaucoma. Additionally, many glaucoma patients have a relatively low IOP, while some healthy individuals have a relatively high IOP. The disorders can be roughly divided into two main categories, open-angle glaucoma and closed-angle glaucoma. Impaired ocular blood flow regulation in open angle glaucoma as a risk of glaucoma has also been well established, especially over the past two decades. Pathophysiology of glaucoma indicates towards the increased in intraocular pressure which compresses and damages the optic nerve. Once the optic nerve is damaged, it fails to carry visual information to the brain and this result in loss of vision. The exact pathophysiology of glaucoma contributing to this is yet to be determined. Biomarkers for glaucoma have predictive use that could help and guide more specific therapy in some glaucoma patients. Endothelin in glaucoma treatment play a very key role in pathogenesis of glaucoma. Glaucoma accounts for over 10 million visits to physicians each year. In terms of Social Security benefits, lost income tax revenues, and health care expenditures, the cost to the U.S. government is estimated to be over $1.5 billion annually. The Glaucoma Research Society of Canada is the only Canadian non-profit organization solely dedicated to funding glaucoma research. Since 1989, it has raised more than two million dollars in support of 150 research projects. The Society funds 10 to 15% of all independent glaucoma research in Canada. Bascom Palmer and Wills Eye are the top researcher organization for glaucoma.
Neuro-ophthalmology is the incorporation of neurology and ophthalmology, often dealing with complex systemic diseases that have manifestations in the visual system. Cerebral Visual Impairment (CVI) includes all visual dysfunctions caused by damage to, or malfunctioning of, the retrochiasmatic visual pathways in the absence of damage to the anterior visual pathways or any major ocular disease. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles which leads to double vision, drooping eyelids and other muscles weakness which effecting the both i.e. neuromuscular activity and also vision. On the other hand nystagmus which is involuntary eye movement acquired in infancy or later in life that may result in reduced or limited vision. Factors like cerebral macular degeneration and chronic progressive external ophthalmoplegia also the major effecting part of neuro-ophthalmology. Diagnostic tools in neuro-ophthalmology are used to investigate and to treat the various condition of neuro-ophthalmology as Neonatal ocular examination are primarily performed to monitor the presence and progression of Retinopathy of Prematurity. University of Pennsylvania is currently working on neuro-ophthalmology project.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Submission InfoFor queries please contact at Email: email@example.com Fax: +1-650-618-1414 Phone: +1-650-268-9744 Toll Free: +1-800-216-6499
In today’s economic climate your business decisions are as crucial as ever. 7th International Conference on Clinical & Experimental Ophthalmology allows you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services.
7th International Conference on Clinical & Experimental Ophthalmology is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in .
Ophthalmology 2016 organizing committee anticipates over 300 participants to attend this premier event. Your organization will benefit with excellent exposure to the leaders in Ophthalmology.
Ophthalmology 2016 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.
Lots of thoughts were put together planning to make this conference a premier event. Our worldwide Editorial Board Members of Journal of Clinical & Experimental Ophthalmology, International Journal of Ophthalmic Pathology and Biological Systems: Open Access have agreed to promote and support the event.
Exhibiting at 7th International Conference on Clinical & Experimental Ophthalmology will attain you with an exceptional format in showcasing your products and services. OMICS International Conferences and Exhibitions provide you one location to reach your top customers.
Drop us an email for Program enquiry.
Sponsors / Exhibiting / Advertising.